Search Results - "Lolli, Ivan"

Crohn’s Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review by Cavalcanti, Elisabetta, Armentano, Raffaele, Lolli, Ivan

“…Recently, there have been a few reports of rituximab (RTX)-induced Crohn’s disease, but there is no literature available on successful long-term treatment and…”
Get full text

Unexpected response to palliative radiotherapy for subcutaneous metastases of an advanced small cell pancreatic neuroendocrine carcinoma: a case report of two different radiation schedules by Ciliberti, Maria Paola, Carbonara, Roberta, Grillo, Antonietta, Leo, Anna Maria, Lolli, Ivan, Ostuni, Carmela, Troiani, Laura, Turi, Barbara, Vallarelli, Simona, Sardaro, Angela

“…Skin metastases from pancreatic neuroendocrine carcinoma (PNEC) are rare and their palliative treatment is challenging. We report our experience in the…”
Get full text

Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol by Bongiovanni, Alberto, Liverani, Chiara, Pusceddu, Sara, Leo, Silvana, Di Meglio, Giovanni, Tamberi, Stefano, Santini, Daniele, Gelsomino, Fabio, Pucci, Francesca, Berardi, Rossana, Lolli, Ivan, Bergamo, Francesca, Ricci, Sergio, Foca, Flavia, Severi, Stefano, Ibrahim, Toni

“…IntroductionPatients with metastatic or locally advanced, non-resectable, grade 3 poorly differentiated gastroenteropancreatic (GEP) and lung neuroendocrine…”
Get full text

Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study by Rosati, Gerardo, Pinto, Carmine, Di Fabio, Francesca, Chiara, Silvana, Lolli, Ivan R., Ruggeri, Enzo M., Ciuffreda, Libero, Ferrara, Raimondo, Antonuzzo, Lorenzo, Adua, Daniela, Racca, Patrizia, Bilancia, Domenico, Benincasa, Elena, Stroppolo, Maria Elena, Di Costanzo, Francesco

“…The influence of age (<70 years and ≥70 years) was retrospectively studied on the quality of life (QoL), incidence of side effects (including skin reactions)…”
Get full text

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study by Pinto, Carmine, Di Fabio, Francesca, Rosati, Gerardo, Lolli, Ivan R., Ruggeri, Enzo M., Ciuffreda, Libero, Ferrari, Daris, Lo Re, Giovanni, Rosti, Giovanni, Tralongo, Paolo, Ferrara, Raimondo, Alabiso, Oscar, Chiara, Silvana, Ianniello, Giovanni P., Frassoldati, Antonio, Bilancia, Domenico, Campanella, Giovanna A., Signorelli, Carlo, Racca, Patrizia, Benincasa, Elena, Stroppolo, Maria Elena, Di Costanzo, Francesco

“…Cetuximab improves efficacy when added to chemotherapy for metastatic colorectal cancer (mCRC). Effective management of skin reactions from cetuximab improves…”
Get full text

Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab-paclitaxel therapy outcome in advanced gastric cancer: results of prospective study by D'Alessandro, Rosalba, Refolo, Maria Grazia, Schirizzi, Annalisa, De Leonardis, Giampiero, Donghia, Rossella, Guerra, Vito, Giannelli, Gianluigi, Lolli, Ivan Roberto, Laterza, Maria Maddalena, De Vita, Ferdinando, Messa, Caterina, Lotesoriere, Claudio

“…[This corrects the article DOI: 10.3389/fonc.2022.862116.]…”
Get full text

Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab-Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study by D'Alessandro, Rosalba, Refolo, Maria Grazia, Schirizzi, Annalisa, De Leonardis, Giampiero, Donghia, Rossella, Guerra, Vito, Giannelli, Gianluigi, Lolli, Ivan Roberto, Laterza, Maria Maddalena, De Vita, Ferdinando, Messa, Caterina, Lotesoriere, Claudio

“…The combination of paclitaxel and ramucirumab is the second-line therapy of choice in the treatment of advanced gastric cancer. To date, no biomarkers are…”
Get full text

A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy by Paccapelo, Alessandro, Lolli, Ivan, Fabrini, Maria Grazia, Silvano, Giovanni, Detti, Beatrice, Perrone, Franco, Savio, Giuseppina, Santoni, Matteo, Bonizzoni, Erminio, Perrone, Tania, Scoccianti, Silvia

“…At recurrence the use of nitrosoureas is widely-used as a therapeutic option for glioblastoma (GBM) patients. The efficacy of fotemustine (FTM) has been…”
Get full text

Long lasting octreotide LAR therapy in non functioning pancreatic neuroendocrine carcinoma by Lolli, Ivan, Logroscino, Antonio, Vallarelli, Simona, Monteduro, Maria A., Gentile, Antonella, Troccoli, Giuseppe

“…Non functioning endocrine pancreatic tumors (NF-PETs) have absent or low hormone secretion without symptoms and constitue ~60% of PETs. At diagnosis more than…”
Get full text

A ruptured gastrointestinal stromal tumour of the small intestine: a case report by Lolli, Ivan, Diotaiuti, Sergio, Russo, Silvana, Campanella, Giovanna A., Giampaolo, Nicola, Leandro, Gioacchino, Defilippis, Vincenzo

“…The management of Gastrointestinal Stromal Tumours (GISTs) has evolved rapidly since imatinib was introduced. Surgery remains the first-line treatment for…”
Get full text

Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas by Quaranta, Michele, Divella, Rosa, Daniele, Antonella, Di Tardo, Silvia, Venneri, Maria Teresa, Lolli, Ivan, Troccoli, Giuseppe

“…The epidermal growth factor receptor (EGFR) is a member of a family of cell membrane receptors that use tyrosine kinase activity as the signal transduction…”
Get full text

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial by Lombardi, Giuseppe, De Salvo, Gian Luca, Brandes, Alba Ariela, Eoli, Marica, Rudà, Roberta, Faedi, Marina, Lolli, Ivan, Pace, Andrea, Daniele, Bruno, Pasqualetti, Francesco, Rizzato, Simona, Bellu, Luisa, Pambuku, Ardi, Farina, Miriam, Magni, Giovanna, Indraccolo, Stefano, Gardiman, Marina Paola, Soffietti, Riccardo, Zagonel, Vittorina

“…Glioblastoma is a highly vascularised tumour and there are few treatment options after disease recurrence. Regorafenib is an oral multikinase inhibitor of…”
Get full text

Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature by Lolli, Ivan, Valentini, Anna Maria, Ricci, Angela Dalia, Armentano, Raffaele

“…Anaplastic classic Kaposi sarcoma (CKS) is an extremely rare pathologic variant of CKS characterized by high aggressiveness and poor prognosis. We report the…”
Get more information

Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines by Refolo, Maria Grazia, Lotesoriere, Claudio, Lolli, Ivan Roberto, Messa, Caterina, D’Alessandro, Rosalba

“…Ramucirumab is approved both as monotherapy and in combination with Paclitaxel for advanced gastric cancer in patients with disease progression after…”
Get full text

A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib by Santangelo, Alessandra, Rossato, Marzia, Lombardi, Giuseppe, Benfatto, Salvatore, Lavezzari, Denise, De Salvo, Gian Luca, Indraccolo, Stefano, Dechecchi, Maria Cristina, Prandini, Paola, Gambari, Roberto, Scapoli, Chiara, Di Gennaro, Gianfranco, Caccese, Mario, Eoli, Marica, Rudà, Roberta, Brandes, Alba Ariela, Ibrahim, Toni, Rizzato, Simona, Lolli, Ivan, Lippi, Giuseppe, Delledonne, Massimo, Zagonel, Vittorina, Cabrini, Giulio

“…Abstract Background Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival (OS) benefit of…”
Get full text

Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial) by Lombardi, Giuseppe, Del Bianco, Paola, Brandes, Alba A., Eoli, Marica, Rudà, Roberta, Ibrahim, Toni, Lolli, Ivan, Rizzato, Simona, Daniele, Bruno, Pace, Andrea, Pasqualetti, Francesco, Caccesse, Mario, Bergo, Eleonora, Magni, Giovanna, De Salvo, Gian Luca, Zagonel, Vittorina

“…The REGOMA trial showed that regorafenib significantly improved overall survival in patients with recurrent glioblastoma compared with lomustine. Patients…”
Get full text

Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis by Indraccolo, Stefano, De Salvo, Gian Luca, Verza, Martina, Caccese, Mario, Esposito, Giovanni, Piga, Ilaria, Del Bianco, Paola, Pizzi, Marco, Gardiman, Marina Paola, Eoli, Marica, Rudà, Roberta, Brandes, Alba Ariela, Ibrahim, Toni, Rizzato, Simona, Lolli, Ivan, Zagonel, Vittorina, Lombardi, Giuseppe

“…Preclinical studies show that antiangiogenic therapy exacerbates tumor glycolysis and activates liver kinase B1/AMP kinase (AMPK), a pathway involved in the…”
Get full text

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas by Bongiovanni, Alberto, Liverani, Chiara, Foca, Flavia, Bergamo, Francesca, Leo, Silvana, Pusceddu, Sara, Gelsomino, Fabio, Brizzi, Maria Pia, Di Meglio, Giovanni, Spada, Francesca, Tamberi, Stefano, Lolli, Ivan, Cives, Mauro, Marconcini, Riccardo, Pucci, Francesca, Berardi, Rossana, Antonuzzo, Lorenzo, Badalamenti, Giuseppe, Santini, Daniele, Recine, Federica, Vanni, Silvia, Tebaldi, Michela, Severi, Stefano, Rudnas, Britt, Nanni, Oriana, Ranallo, Nicoletta, Crudi, Laura, Calabrò, Luana, Ibrahim, Toni

“…Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line…”
Get full text

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology) by Soffietti, Riccardo, Trevisan, Elisa, Bertero, Luca, Cassoni, Paola, Morra, Isabella, Fabrini, Maria Grazia, Pasqualetti, Francesco, Lolli, Ivan, Castiglione, Anna, Ciccone, Giovannino, Rudà, Roberta

“…The optimal combination of bevacizumab with cytotoxic or cytostatic drugs in recurrent glioblastoma is unknown. We performed a phase 2 trial of combined…”
Get full text

Intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study by Avallone, Antonio, Giuliani, Francesco, Nasti, Guglielmo, Montesarchio, Vincenzo, Santabarbara, Giuseppe, Leo, Silvana, Malapelle, Umberto, De Stefano, Alfonso, Rosati, Gerardo, Lolli, Ivan, Tamburini, Emiliano, Colombo, Alfredo, Santini, Daniele, Silvestro, Lucrezia, Leone, Alessandra, Vitagliano, Carlo, Troncone, Giancarlo, Sobrero, Alberto F., Giannarelli, Diana, Budillon, Alfredo

“…3571 Background: IMPROVE is a randomized, non-comparative multicenter, phase 2 study which evaluated continuous, until progressive disease (PD), or…”
Get full text